Story perspectives

Biotech Sector Optimistic Amid $300 Billion Patent Cliff

1/20/2026

43 7

Summary

Story summary

The biotech sector enters 2026 with optimism due to market recovery and metabolic health competition.
Major players Eli Lilly, AbbVie, and Roche lead as the industry faces a looming $300 billion patent cliff.
Sanofi and AstraZeneca assess the impact of pricing deals on their businesses, with AstraZeneca noting manageable effects.
JPMorgan Healthcare Conference underscores optimism for dealmaking despite uncertainties as Bristol Myers Squibb and Novo Nordisk prepare for patent expirations.

1 of 1

Story summary

The biotech sector enters 2026 with optimism due to market recovery and metabolic health competition.
Major players Eli Lilly, AbbVie, and Roche lead as the industry faces a looming $300 billion patent cliff.
Sanofi and AstraZeneca assess the impact of pricing deals on their businesses, with AstraZeneca noting manageable effects.
JPMorgan Healthcare Conference underscores optimism for dealmaking despite uncertainties as Bristol Myers Squibb and Novo Nordisk prepare for patent expirations.